Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update - Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to l

Adaptimmune Reports Fourth Quarter /

Full Year 2019 Financial Results and Business Update

- Compelling data in synovial sarcoma in

the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP A2M4 for sarcoma in 2022

- Encouraging demonstration

of the potential of SPEAR T-cell platform in four new solid tumor indications -

- Co-development and co-commercialization

agreement with Astellas to develop stem-cell derived

off-the-shelf' CAR-T and TCR T-cell therapies -

PHILADELPHIA, Pa. and OXFORD, U.K., February 27, 2020 -

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer,

today reported financial results for the fourth quarter and year ended December 31, 2019, and provided a business update.

"The last 12 months have been transformative. We reported

responses in five different solid tumors, confirming that our SPEAR T-cell platform can treat a wide range of cancers. We also

validated the potential of our allogeneic platform by demonstrating that we can generate functional T-cells from stem cells, and

by signing our first major strategic deal in five years with Astellas," said Adrian Rawcliffe, Adaptimmune's Chief

Executive Officer. "With our passionate and skilled teams, and our world class capabilities, we are developing our cell therapy

pipeline for a range of tumor indications, aiming to launch our first product in 2022 for people with sarcoma."

Responses in five solid tumor indications demonstrate

SPEAR T-cell potential to treat cancer

Based on compelling response data in synovial sarcoma from the

Phase 1 trial announced in May of last year, and updated at ESMO and CTOS, the Phase 2 SPEARHEAD-1 trial was initiated with ADP-A2M4

in synovial sarcoma and myxoid/ round cell liposarcoma (MRCLS). The product was granted Orphan Drug Designation, for the treatment

of soft tissue sarcomas, and Regenerative Medicine Advanced Therapy designation, for synovial sarcoma, by the US FDA. The Company

aims to launch ADP A2M4 for sarcoma in 2022.

In January of this year, partial responses in

liver, melanoma, gastro-esophageal junction, and head and neck cancers were reported. These early data in multiple indications

demonstrate the potential of Adaptimmune's SPEAR T-cell platform across multiple targets and a range of solid tumors. Further

updated data will be presented at upcoming medical / scientific meetings.

Partnerships to develop next-generation and off-the-shelf

In January of this year, a co-development and co-commercialization

agreement with Astellas, through its wholly owned subsidiary Universal Cells, Inc., was announced for stem-cell derived allogeneic

CAR-T and TCR T-cell therapies. The Company has received an upfront payment of $50 million under the agreement and is entitled

to receive research funding of up to $7.5 million per year.

This agreement covers the co-development and

co-commercialization of up to three T-cell therapies and leverages Astellas' Universal Donor Cell Platform and

Adaptimmune's stem-cell derived allogeneic T-cell platform. This new

collaboration may encompass both CAR-T and TCR T-cell approaches, including Adaptimmune's novel HLA-independent TCR

In 2019, Adaptimmune announced

agreements with Alpine Immune Sciences and Noile-Immune to develop further next-generation products.

Leadership, manufacturing and financial updates strengthen

fully integrated cell therapy company position

Adrian Rawcliffe assumed the role of Chief Executive Officer

effective September 1, 2019 and John Lunger became Chief Patient Supply Officer effective August 1, 2019. In January 2020, a series

of changes to the R&D leadership were announced, including the appointment of Elliot Norry as Chief Medical Officer. These

leadership changes strengthen the scientific and clinical organization from early to late stage and accelerate the application

of translational science learnings to therapeutic candidates and trials, as Adaptimmune becomes a late-stage cell therapy company

aiming to launch a commercial product in 2022.

Adaptimmune's in-house cell manufacturing facility located

at the Navy Yard in Philadelphia, PA, is achieving a 25-day processing time for production of SPEAR T-cells. 95% of patient batches

manufactured in 2019 met manufacturing criteria set for those batches. The Navy Yard facility was approved as a manufacturing source

for a number of the Company's clinical trials in Europe. The Company also produced its first GMP batch of lentiviral vector

using an in-house, proprietary suspension process at its dedicated manufacturing space within the Cell and Gene Therapy Catapult

Manufacturing Centre at Stevenage, UK.

Finally, on January 24, 2020, the Company closed an underwritten

public offering of 21,000,000 American Depository Shares (ADSs) which, together with the full exercise by the underwriters on February

7, 2020 of their option to purchase an additional 3,150,000 ADSs, generated net proceeds of approximately $89.8 million. Following

the agreement with Astellas and the public offering of ADSs described above, the Company is funded into 2H 2021.

Planned 2020 milestones

Financial Results for the fourth quarter and year ended

The Company believes that its existing cash and cash equivalents

and marketable securities, Total Liquidity, together with the net proceeds received from the underwritten public offering in January

2020, the additional net proceeds generated from the exercise in full of the underwriters' option in February 2020 and the

upfront payment received under its agreement with Astellas in January 2020, will fund the Company's current operating plan

into the second half of 2021.

Conference Call Information

The Company will host a live teleconference and webcast to provide

additional details at 8:00 a.m. EST (1:00 p.m. GMT) today, February 27, 2020. The live webcast of the conference call will be available

via the events page of Adaptimmune's corporate website at www.adaptimmune.com. An archive will be available after the call

at the same address. To participate in the live conference call, if preferred, please dial (833) 652-5917 (U.S. or Canada) or +1

(430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide

the confirmation code (6083408).

Adaptimmune is a clinical-stage biopharmaceutical company

focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique

SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and

destroy cancer across multiple solid tumors.

liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures

prepared in accordance with GAAP below.

Forward-Looking Statements

This release contains "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain

risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated

by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities

and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization

processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from

those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our

Quarterly Report on Form 10-Q filed with the SEC on November 6, 2019, and our other SEC filings. The forward-looking statements

contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update

such forward-looking statements to reflect subsequent events or circumstances.

Total Liquidity (a non-GAAP financial measure)

Total Liquidity is the total of cash and cash equivalents and

marketable securities. Each of these components appears in the Company's Consolidated Balance Sheet. The U.S. GAAP financial

measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the Company's Consolidated

Financial Statements, which reconciles to Total Liquidity as follows (unaudited):

The Company believes that the presentation of Total Liquidity

provides useful information to investors because management reviews Total Liquidity as part of its management of overall liquidity,

financial flexibility, capital structure and leverage. The definition of Total Liquidity includes marketable securities, which

are highly liquid and available to use in our current operations.